#Japan #Tokyo #Neurotech Medical #Family Supernatant #StemCell Institute

Collaboration Announcement

StemCell Institute Inc., based in Minato-ku, Tokyo, has recently joined forces with NeuroTech Medical Co., Ltd., headquartered in Joto-ku, Osaka. Beginning on July 3, 2026, this partnership focuses on utilizing umbilical cord-derived stem cell culture supernatant, known as "Family Supernatant," in neuroregeneration.

Partnership Highlights

This collaboration combines the strengths of both organizations—StemCell Institute, a leading entity in the private cord blood banking sector in Japan, and NeuroTech Medical, which offers innovative medical services through its patented neuroregenerative technology. The primary goal is to develop comprehensive medical services capitalizing on both companies' expertise.

Physicians at NeuroTech Medical’s affiliated clinics will work closely with StemCell Institute, which will handle the production of the Family Supernatant using umbilical cord-derived stem cells stored at their facility. This particular service, currently unique to StemCell Institute in Japan, aims to provide tailored treatment options for neuroregenerative medical care.

Understanding Family Supernatant

The Family Supernatant is a proprietary product made from umbilical cord-derived stem cells belonging to a child whose cells have been preserved at the StemCell Institute. This unique offering, known as “ファミリー上清®” in Japan, represents a significant advancement in regenerative medicine. Its English translation, Family Supernatant, underscores its innovative nature and the potential benefits it holds for patients.

ReNeuro: NeuroTech Medical's Approach

NeuroTech Medical's ReNeuro service integrates specialized neuroregenerative technology and targeted rehabilitation methodologies. Under this collaboration, medical professionals will assess the application of Family Supernatant as a potential treatment option, guided by each patient's unique medical circumstances.

Minimal Financial Impact

The expected financial implications of this partnership on StemCell Institute's overall results are anticipated to be modest. Nonetheless, the partnership is positioned as a pivotal move towards expanding their preventive and therapeutic offerings in neuroregeneration.

Corporate Overview

StemCell Institute Inc.

• - Founded: August 5, 1999 (Listed on TSE Growth: 7096)
• - Capital: JPY 704.8 million
• - President: Takafumi Shimizu
• - Headquarters: 2F Tokyu Toranomon Building, 1-21-19 Toranomon, Minato-ku, Tokyo 105-0001
• - Contact: +81-3-6811-3230 / Website
• - Group Companies: STEMCELL INNOVATIONS PTE. LTD. (Singapore), Milcare Co., Ltd.

NeuroTech Medical Co., Ltd.

• - Founded: December 27, 2019
• - Capital: JPY 349,844,000
• - President: Nagatoshi Kihoin
• - Headquarters: Murakami Jitsugyo Building 216, 1-13-13 Chuo, Joto-ku, Osaka 536-0005, Japan
• - Contact: +81-6-7777-4685 / Website

NeuroTech Medical is dedicated to enhancing recovery for patients affected by neurological disorders, actively collaborating to refine its regenerative medicine approach. This partnership promises to forge new paths in the treatment of conditions like strokes and spinal cord injuries, creating significant opportunities for improvement in patient care and outcomes.

An exciting journey into the future of neuroregeneration begins with this collaboration, aiming to deliver hope and healing through cutting-edge medical science.